| Case Number |
Title |
Non-Confidential Summary |
Issued Patent |
Lead Inventor's Website |
| BAR_GIA.007
|
A new way of stimulating the nerves fibers in the lumbar area to relieve severe intractable low back pain
|
|
|
|
| BER_ERI.001
|
Use of Tempol in the Prevention of Photoaging
|
|
[US Patent No. 5,840,734]
|
Link
|
| BER_WOL.001
|
CalDAG-GEFI Inhibitors as Anti-Platelet Drugs
|
NCS for BER_WOL.001 |
|
|
| BLO_TIM.002
|
Glucosidase Inhibitors as a Treatment for Viruses that Bud from the Endoplasmic Reticulum
|
|
|
|
| CON_PAU.001
|
Use Of Magnetic Particles In The Focal Delivery Of Cells
|
|
[US Patent No. 6,203,487]
|
|
| CRO_CAR.002
|
Compositions, Kits and Methods Relating to the Human FEZ1 Gene, a Novel Tumor Suppressor Gene
|
NCS for Croce tumor suppressor techs (CRO 2,4,5,16) |
|
|
| CRO_CAR.004
|
The Human FHIT Gene
|
NCS for Croce tumor suppressor techs (CRO 2,4,5,16) |
[United States Patent: 7220834]
[United States Patent: 6774217]
[United States Patent: 6242212]
[United States Patent: 5928884]
|
|
| CRO_CAR.009
|
TCL-1 Gene And Protein And Related Methods And Compositions
|
NCS for Croce TCL-1 techs (CRO 9,15) |
|
|
| CRO_CAR.015
|
Human Chronic Lymphocytic Leukemia Modeled in Mouse by Targeted TCL1 Expression
|
NCS for Croce TCL-1 techs (CRO 9,15) |
|
|
| CRO_CAR.016
|
Novel Tumor Suppressor Gene and Compositions and Methods for Making and Using the Same
|
NCS for Croce tumor suppressor techs (CRO 2,4,5,16) |
|
|
| CRO_CAR.017
|
Role of microRNA Genes In Human Cancer
|
NCS for Croce miRNA techs (CRO 17, 25) |
|
|
| CRO_CAR.019
|
Involvement Of The ALL-1 Gene In A Solid Tumor1
|
|
[US Patent No. 5,567,586]
|
|
| CRO_CAR.025
|
microRNA genes in cancer diagnosis and treatment
|
NCS for Croce miRNA techs (CRO 17, 25) |
|
|
| DAN_REN.001
|
Inhibition of HIV-1 replication in human peripheral blood monocytes through a clinically used drug
|
|
|
Link
|
| DES_SCO.007
|
Human Antibodies that Bind Amyloid Proteins
|
|
|
|
| DIE_BER.010
|
Recombinant Rabies for Pre- and Post-Exposure Prophylaxis
|
|
|
Link
|
| FOR_FLE.002
|
Selection of Subharmonic Pressure Estimates
|
NCS for FOR_FLE.002 |
|
Link
|
| HOL_MIC.001
|
Inhibitors of Human 12-Lipoxygenase
|
|
|
|
| HOU_YAM.005
|
Apoptosis of Cardiomyocytes
|
|
|
Link
|
| HOU_YAM.006
|
Antibiotics Targeting a Growth-Dependent Bacterial Enzyme
|
|
|
Link
|
| IOZ_REN.001
|
A Role For Decorin In Tumor Suppression
|
|
[US Patent No. 6,524,573]
|
Link
|
| IWA_MAS.003
|
Pharmacologic Treatment for Muscle Repair
|
NCS for IWA_MAS.003 |
|
Link
|
| KAS_DAV.001
|
A Small Bowel Purgative for Wireless Capsule Endoscopy
|
NCS for KAS_DAV.001 |
|
|
| KMI_ERI.005
|
Methods for Enhancing Gene Conversion or Genetic Repair by Chimeric Oligonucleotides
|
|
|
|
| KOC_WAL.005
|
Adrenal Beta-Arrestin 1 is a Critical Regulator of Post-Myocardial Infarction Aldosterone Levels During Progression to Heart Failure
|
|
|
Link
|
| KOP_HIL.006
|
Polypeptides Fused with Alfalfa Mosaic Virus or Ilarvirus Capsid Proteins
|
|
[US Patent No. 6,042,832]
[US Patent No. 6,448,070]
|
Link
|
| KWO_SIM.001
|
Novel Tumor Suppressor Encoding Nucleic Acid, PTX1, and Methods of Use Thereof
|
NCS for KWO_SIM.001 |
[US Patent No. 6,743,603]
|
|
| MCM_STE.002
|
Novel Mechanism for Control of AR Function in Prostate Cancer
|
|
|
|
| MEN_SUE.004
|
Method for Treatment of PCO
|
|
|
Link
|
| OST_JEW.002
|
Intra-Peritoneal Perfusion of Oxygenated Fluorocarbons
|
|
[US Patent No. 4,657,532]
[US Patent No. 4,963,130]
|
Link
|
| PEZ_TIF.001H
|
Secretion Free Continuous Nebulizer
|
NCS for PEZ_TIF.001H |
|
|
| POD_TAR.005
|
Robotic Biopsy and Lumpectomy
|
|
|
|
| PRI_EDM.005
|
A Pocketsized Medical Auto-Injector
|
NCS for PRI_EDM.005 |
|
Link
|
| RAB_JOS.001
|
Development of an Enhancer/Promoter Pair for Heart Selective Gene Expression
|
NCS for RAB_JOS.001 |
|
Link
|
| SAN_JAM.001
|
Peptides with High Affinity for Heparin and for Proteoglycans to be used to Promote Endothelialization of Synthetic Vascular Graft Surfaces, or to Target the Delivery of Drugs to Cell Surfaces
|
NCS for SAN_JAM.001, .002 |
[US Patent No. 6,855,801]
|
Link
|
| SAN_JAM.002
|
Peptides that Neutralize Heparin or Proteoglycans, or Promote Cell Adhesion or Drug Delivery
|
NCS for SAN_JAM.001, .002 |
[US Patent No. 7,259,140]
|
Link
|
| SCH_JAY.001
|
Treatment of Parkinson's Disease with Oligonucleotide and Triplex Technology
|
NCS for SCH_JAY.001, 002, 004, 008 |
|
Link
|
| SCH_JAY.002
|
Partial Agonists at the Glycine Modulatory Site of the NMDA Receptor for Treating Cognitive Dysfunction in Parkinson's Disease
|
NCS for SCH_JAY.001, 002, 004, 008 |
|
Link
|
| SCH_JAY.004
|
Method of Treating Parkinson's Disease and Composition for the Same
|
NCS for SCH_JAY.001, 002, 004, 008 |
[United States Patent: 7160913]
|
Link
|
| SCH_JAY.008
|
Treatment of Parkinson's Disease and Parkinson's Disease Treatment-related Complications with RNA Inhibition Therapies
|
NCS for SCH_JAY.001, 002, 004, 008 |
|
Link
|
| SCH_MAT.010
|
Polypeptides Inducing Neuron Survival, Polynucleotides Encoding Them and Therapeutic Uses Thereof
|
|
|
Link
|
| SHI_YI.008
|
Prevention and Treatment of Metabolic Disorder-Associated Osteopenia/Osteoporosis and Bone Marrow Abnormalities
|
|
|
|
| SHI_YI.010
|
Prevention and Treatment of Vascular Dementia and Alzheimer's Disease
|
|
|
|
| STR_DAV.001
|
SV40 Viral Vectors for Targeted Integration Into Cells
|
|
[US Patent No. 5,863,794]
|
Link
|
| SUN_XIA.001
|
Implantable Sensor and System for Measurement and Control of Blood Constituent Levels
|
|
[US Patent No. 5,995,860]
[US Patent No. 6,122,536]
|
|
| SYK_YUR.004
|
Invention of a Novel Serum Free Media for Cultivation of Hybridoma Cells to Achieve Production of Highly Homogenous Monoclonal Antibodies (MAb) in Preparative Scale
|
NCS for SYK_YUR.004 |
|
Link
|
| THA_MAT.002
|
Lipid soluble radioactive metal chelates for tumor therapy
|
NCS for THA_MAT.002 |
[US Patent No. 6,685,913]
|
Link
|
| THO_JEF.001
|
Nitric Oxide Donor Compositions, Methods, Apparatus, and Kits for Alleviating Vasoconstriction and Vasospasm in a Mammal
|
|
[US Patent No. 6,358,536]
|
|
| WIL_JOH.005
|
Design and Development of Masked Therapeutic Antibodies to Limit Off-Target Effects: Application to Anti-EGFR Antibodies (Also known as "EGFR-Specific ScFvs Engineered to Enable Selective Antigen Recognition Upon Proteolytic Activation")
|
|
|
|
| ZAL_AND.002
|
Inhibition of Extracellular Matrix Synthesis By Antisense Compounds Directed to Nuclear Proto-Oncogenes
|
|
[US Patent No. 6,133,242]
|
|
